Bone Biologics Corp (BBLG) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bone Biologics Corporation on June 6, 2023, reporting events occurring on June 5, 2023. The Company is incorporated in Delaware and its common stock and warrants trade on The Nasdaq Capital Market under the symbols BBLG and BBLGW, respectively.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a corporate action regarding capital structure.
Material Changes
On June 5, 2023, the Company implemented a 1-for-30 reverse stock split of its outstanding common stock and warrants. This action was authorized by stockholders via written consent on May 1, 2023, and became effective on June 5, 2023. Key details include:
- Every 30 shares of issued and outstanding common stock were automatically combined into one share.
- Proportionate adjustments were made to the exercise price and number of shares issuable for all outstanding stock options and warrants.
- Fractional shares resulting from the split were rounded up to the nearest whole share.
- The Company's percentage ownership for stockholders remained unchanged, except for those holding only fractional shares.
Outlook, Risks, and Unusual Items
Trading on The Nasdaq Capital Market resumed on a split-adjusted basis on June 7, 2023. The Company assigned new CUSIP numbers for the post-split securities: 098070402 for common stock and 098070154 for warrants. No specific guidance, risks, or contingencies beyond the mechanics of the reverse split were disclosed in this filing.
Investor Verification Checklist
- Verify the new CUSIP numbers (098070402 for stock, 098070154 for warrants) in brokerage accounts.
- Confirm that stock option and warrant exercise prices have been adjusted proportionately (increased 30x) and share counts reduced (divided by 30).
- Check for any fractional share rounding adjustments in personal holdings.
- Review the Certificate of Amendment (Exhibit 3.1) for specific legal terms of the capitalization change.